Potential roles for the PIM1 kinase in human cancer - A molecular and therapeutic appraisal

European Journal of Cancer

Volumn 44, Issue 15, 2008, Pages 2144-2151

  Shah, Nilesh ^a   Pang, Brendan ^b   Yeoh, Khay Guan ^a,c   Thorn, Shannon ^d   Chen, Chien Shing ^a,c   Lilly, Michael B ^e   Salto Tellez, Manuel ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d UNIVERSITY OF ARIZONA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Carcinomas; Kinase; Lymphomas; PIM1; Target inhibitors

Indexed keywords

PROTEIN KINASE PIM 1; RUBOXISTAURIN;

ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER GROWTH; CANCER SURVIVAL; DISEASE COURSE; GASTROINTESTINAL TUMOR; HEMATOPOIETIC SYSTEM TUMOR; HORMONE RESISTANCE; HUMAN; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN EXPRESSION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-PIM-1; TUMOR MARKERS, BIOLOGICAL;

EID: 53249137796     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.06.044     Document Type: Article

References (76)

1. Nagarajan L., Louie E., Tsujimoto Y., ar-Rushdi A., Huebner K., and Croce C.M. Localization of the human PIM oncogene (PIM) to a region of chromosome 6 involved in translocations in acute leukemias. Proc Natl Acad Sci U S A 83 (1986) 2556-2560
2. Zakut-Houri R., Hazum S., Givol D., and Telerman A. The cDNA sequence and gene analysis of the human PIM oncogene. Gene 54 (1987) 105-111
3. Saris C.J., Domen J., and Berns A. The PIM1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J 10 (1991) 655-664
4. Reeves R., Spies G.A., Kiefer M., Barr P.J., and Power M. Primary structure of the putative human oncogene, PIM1. Gene 90 (1990) 303-307
5. Liang H., Hittelman W., and Nagarajan L. Ubiquitous expression and cell cycle regulation of the protein kinase PIM1. Arch Biochem Biophys 330 (1996) 259-265
6. Palaty C.K., Clark-Lewis I., Leung D., and Pelech SL Phosphorylation site substrate specificity determinants for the PIM1 protooncogene-encoded protein k. Biochem Cell Biol 75 (1997) 153-162
7. Qian K.C., Wang L., Hickey E.R., et al. Structural basis of constitutive activity and a unique nucleotide binding mode of human PIM1 kinase. J Biol Chem 280 (2005) 6130-6137
8. Ionov Y., Le X., Tunquist B.J., et al. PIM1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects. Anticancer Res 23 (2003) 167-178
9. Aho T.L., Lund R.J., Ylikoski E.K., Matikainen S., Lahesmaa R., and Koskinen P.J. Expression of human PIM family genes is selectively up-regulated by cytokines promoting T helper type 1, but not T helper type 2, cell differentiation. Immunology 116 (2005) 82-88
10. Matikainen S., Sareneva T., Ronni T., Lehtonen A., Koskinen P.J., and Julkunen I. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and PIM1 genes in human T cells. Blood 93 (1999) 1980-1991
11. Temple R., Allen E., Fordham J., et al. Microarray analysis of eosinophils reveals a number of candidate survival and apoptosis genes. Am J Respir Cell Mol Biol 25 (2001) 425-433
12. Qian J., Niu J., Li M., Chiao P.J., and Tsao M.S. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis. Cancer Res 65 (2005) 5045-5053
13. Rimon E., Sasson R., Dantes A., Land-Bracha A., and Amsterdam A. Gonadotropin-induced gene regulation in human granulosa cells obtained from IVF patients: modulation of genes coding for growth factors and their receptors and genes involved in cancer and other diseases. Int J Oncol 24 (2004) 1325-1338
14. Barrier A., Olaya N., Chiappini F., et al. Ischemic preconditioning modulates the expression of several genes, leading to the overproduction of IL-1Ra, iNOS, and Bcl-2 in a human model of liver ischemia-reperfusion. FASEB J 19 (2005) 1617-1626
15. Le Q.T., Denko N.C., and Giaccia A.J. Hypoxic gene expression and metastasis. Cancer Metastasis Rev 23 (2004) 293-310
16. Rainio E.M., Ahlfors H., Carter K.L., et al. PIM kinases are upregulated during Epstein-Barr virus infection and enhance EBNA2 activity. Virology 333 (2005) 201-206
17. Sepulveda A.R., Tao H., Carloni E., Sepulveda J., Graham D.Y., and Peterson L.E. Screening of gene expression profiles in gastric epithelial cells induced by Helicobacter pylori using microarray analysis. Aliment Pharmacol Ther 16 Suppl 2 (2002) 14-57
18. Bachmann M., and Möröy T. The serine/threonine kinase Pim-1. Int J Biochem Cell Biol 37 (2005) 726-730
19. Wang Z., Bhattacharya N., Weaver M., et al. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2 (2001) 167-179
20. Chen X.P., Losman J.A., Cowan S., et al. Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci U S A 99 (2002) 2175-2180
21. Leverson J.D., Koskinen P.J., Orrico F.C., et al. Pim-1 kinase and p100 cooperate to enhance c-Myb activity. Mol Cell 2 (1998) 417-425
22. Rainio E.M., Sandholm J., and Koskinen P.J. Cutting edge: Transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase. J Immunol 168 (2002) 1524-1527
23. Koike N., Maita H., Taira T., Ariga H., and Iguchi-Ariga S.M. Identification of heterochromatin protein 1 (HP1) as a phosphorylation target by Pim-1 kinase and the effect of phosphorylation on the transcriptional repression function of HP1(1). FEBS Lett 467 (2000) 17-21
24. Maita H., Harada Y., and Nagakubo D. PAP-1, a novel target protein of phosphorylation by pim-1 kinase. Eur J Biochem 267 (2000) 5168-5178
25. Mochizuki T., Kitanaka C., Noguchi K., Muramatsu T., Asai A., and Kuchino Y. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 274 (1999) 18659-18666
26. Bachmann M., Hennemann H., Xing P.X., Hoffmann I., and Möröy T. The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 279 (2004) 48319-48328
27. Wang Z., Bhattacharya N., Mixter P.F., Wei W., Sedivy J., and Magnuson N.S. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 1593 (2002) 45-55
28. Bhattacharya N., Wang Z., Davitt C., McKenzie I.F., Xing P.X., and Magnuson N.S. Pim-1 associates with protein complexes necessary for mitosis. Chromosoma 111 (2002) 80-95
29. Shirogane T., Fukada T., Muller J.M., Shima D.T., Hibi M., and Hirano T. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 11 (1999) 709-719
30. Aho T.L., Sandholm J., Peltola K.J., Mankonen H.P., Lilly M., and Koskinen P.J. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 571 (2004) 43-49
31. Nieborowska-Skorska M., Hoser G., Kossev P., Wasik M.A., and Skorski T. Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase PIM1 in the BCR/ABL-mediated leukemogenesis. Blood 99 (2002) 4531-4539
32. Kim K.T., Baird K., Ahn J.Y., et al. PIM1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 105 (2005) 1759-1767
33. Valk P.J., Verhaak R.G., Beijen M.A., et al. Prognostically useful gene-expression profiles in acute myeloid leukaemia. N Engl J Med 350 (2004) 1617-1628
34. Zippo A., De Robertis A., Bardelli M., Galvagni F., and Oliviero S. Identification of Flk-1 target genes in vasculogenesis: PIM1 is required for endothelial and mural cell differentiation in vitro. Blood 103 (2004) 4536-4544
35. de Vos S., Krug U., Hofmann W.K., et al. Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV. Diagn Mol Pathol 12 (2003) 35-43
36. Deutsch A., Aigelsreiter A., Beham-Schmid C., Beham A., Linkesch W., and Neumeister P. Aberrant somatic hypermutation in extranodal marginal zone B-cell lymphoma of MALT type. Blood 106 (2005) 125a-126a Abstr 417
37. Hoefnagel J.J., Dijkman R., Basso K., et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 105 (2005) 3671-3678
38. Chen W.W., Chan D.C., Donald C., Lilly M.B., and Kraft A.S. PIM family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res 3 (2005) 443-451
39. Chen C.N., Lin J.J., Chen J.J., et al. Gene expression profile predicts patient survival of gastric cancer after surgical resection. J Clin Oncol 23 (2005) 7286-7295
40. Cuypers H.T., Selten G., Quint W., et al. Murine leukaemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 37 (1984) 141-150
41. Akasaka H., Akasaka T., Kurata M., et al. Molecular anatomy of BCL6 translocations revealed by long-distance polymerase chain reaction-based assays. Cancer Res 60 (2000) 2335-2341
42. Sivertsen E.A., Galteland E., Mu D., et al. Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas. Leukaemia 20 (2006) 539-542
43. Pasqualucci L., Neumeister P., Goossens T., et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412 (2001) 341-346
44. Gaidano G., Pasqualucci L., Capello D., et al. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood 102 (2003) 1833-1841
45. Libra M., Capello D., Gloghini A., et al. Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection. J Pathol 206 (2005) 87-91
46. Montesinos-Rongen M., Van Roost D., Schaller C., Wiestler O.D., and Deckert M. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 103 (2004) 1869-1875
47. Kumar A., Mandiyan V., Suzuki Y., et al. Crystal structures of proto-oncogene kinase PIM1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol 348 (2005) 183-193
48. Wright G., Tan B., Rosenwald A., Hurt E.H., Wiestner A., and Staudt L.M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 100 (2003) 9991-9996
49. Cohen J.I., and Kieff E. An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator. J Virol 65 (1991) 5880-5885
50. Pomerantz J., Schreiber-Agus N., Liegeois N.J., et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92 (1998) 713-723
51. Zhu Y., Hollmen J., Raty R., et al. Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br J Haematol 119 (2002) 905-915
52. von Lindern M., van Agthoven T., Hagemeijer A., Adriaansen H., and Grosveld G. The human pim-1 gene is not directly activated by the translocation (6;9) in acute nonlymphocytic leukemia. Oncogene 4 (1989) 75-79
53. Meeker T.C., Loeb J., Ayres M., and Sellers W. The human PIM1 gene is selectively transcribed in different hemato-lymphoid cell lines in spite of a G + C-rich housekeeping promoter. Mol Cell Biol 10 (1990) 680-688
54. Betts D.R., Stanchescu R., Niggli F.K., et al. SKY reveals a high frequency of unbalanced translocations involving chromosome 6 in t(12;21)-positive acute lymphoblastic leukemia. Leuk Res 32 (2008) 39-43
55. Valdman A., Fang X., Pang S.T., Ekman P., and Egevad L. PIM1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate 60 (2004) 367-371
56. Roh M., Gary B., Song C., et al. Overexpression of the oncogenic kinase PIM1 leads to genomic instability. Cancer Res 63 (2003) 8079-8084
57. Thompson J., Peltola K.J., Koskinen P.J., Janne O.A., and Palvimo J.J. Attenuation of androgen receptor-dependent transcription by the serine/threonine kinase PIM1. Lab Invest 83 (2003) 1301-1309
58. Dhanasekaran S.M., Barrette T.R., Ghosh D., et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412 (2001) 822-826
59. Cibull T.L., Jones T.D., Li L., et al. Overexpression of PIM1 during progression of prostatic adenocarcinoma. J Clin Pathol 59 (2006) 285-288
60. Ragin C.C., Reshmi S.C., and Gollin S.M. Mapping and analysis of HPV16 integration sites in a head and neck cancer cell line. Int J Cancer 110 (2004) 701-709
61. Stewart B.E., and Rice R.H. Differentiation-associated expression of the proto-oncogene PIM1 in cultured human keratinocytes. J Invest Dermatol 105 (1995) 699-703
62. Jeon G.A., Lee J.S., Patel V., et al. Global gene expression profiles of human head and neck squamous carcinoma cell lines. Int J Cancer 112 (2004) 249-258
63. Alevizos I., Mahadevappa M., Zhang X., et al. Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. Oncogene 20 (2001) 6196-6204
64. Buchholz M., Braun M., Heidenblut A., et al. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 24 (2005) 6626-6636
65. Lee J.Y., Park Y.N., Uhm K.O., Park S.Y., and Park S.H. Genetic alterations in intrahepatic cholangiocarcinoma as revealed by degenerate oligonucleotide primed PCR-comparative genomic hybridization. J Korean Med Sci 19 (2004) 682-687
66. Kim T.M., Yim S.H., Lee J.S., et al. Genome-wide screening of genomic alterations and their clinicopathologic implications in non-small cell lung cancers. Clin Cancer Res 11 (2005) 8235-8242
67. Lam L.T., Davis R.E., Pierce J., et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 11 (2005) 28-40
68. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362 (1993) 841-844
69. Katakami N., Kaneto H., Hao H., et al. Role of PIM1 in smooth muscle cell proliferation. J Biol Chem 279 (2004) 54742-54749
70. Jacobs M.D., Black J., Futer O., et al. PIM1 Ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J Biol Chem 280 (2005) 13728-13734
71. Pogacic V., Bullock A.N., Fedorov O., et al. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res 67 (2007) 6916-69124
72. Fedorov O., Marsden B., Pogacic V., et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A 104 (2007) 20523-20528
73. Holder S., Zemskova M., Zhang C., et al. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 6 (2007) 163-172
74. Cheney I.W., Yan S., Appleby T., et al. Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 17 (2007) 1679-1683
75. Traverse-Glehen A., Verney A., Baseggio L., et al. Analysis of IgVH, BCL-6, PIM, RHO/TTF and PAX5 mutational status in splenic and nodal marginal zone B cell lymphoma suggests a particular B cell origin. Blood 106 (2005) 51a Abstr162
76. Stokke T., DeAngelis P., Smedshammer L., et al. Loss of chromosome 11q21-23. 1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma. Br J Cancer 85 (2001) 1900-1913